What have we learnt about the management of diabetic macular edema in the antivascular endothelial growth factor and corticosteroid era?

Aniruddha Agarwal, Salman Sarwar, Yasir J. Sepah, Quan D. Nguyen

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Purpose of review To summarize the outcomes of the use of antivascular endothelial growth factor (anti-VEGF) agents and corticosteroids on the treatment paradigm for diabetic macular edema (DME). Recent findings Favorable efficacy data along with acceptable long-term safety results of anti-VEGF agents have made them the standard first-line therapy in the management of DME. Level I evidence from large, multicenter clinical trials has established the beneficial role of anti-VEGF agents and intravitreal steroids. In addition, the role of anti-VEGF agents in the treatment of diabetic retinopathy has also been recently recognized. However, concerns such as suboptimal response, VEGF resistance, and long-term effects on retinal layers and vasculature have also been highlighted recently. Summary The use of anti-VEGF agents and corticosteroids has revolutionized the management of DME. Despite the advantages including ease of administration, low incidence of adverse events, and concomitant improvement in retinopathy status, limitations of this therapeutic approach have been recognized. The current review will focus on the lessons learnt in the management of DME in the anti-VEGF and steroid era.

Original languageEnglish (US)
Pages (from-to)177-183
Number of pages7
JournalCurrent Opinion in Ophthalmology
Volume26
Issue number3
DOIs
StatePublished - May 9 2015

Fingerprint

Endothelial Growth Factors
Macular Edema
Adrenal Cortex Hormones
Steroids
Diabetic Retinopathy
Vascular Endothelial Growth Factor A
Multicenter Studies
Clinical Trials
Safety
Incidence
Therapeutics

Keywords

  • antivascular endothelial growth factor
  • corticosteroids
  • diabetic macular edema
  • intravitreal injection
  • laser photocoagulation
  • neovascularization
  • vascular endothelial growth factor

ASJC Scopus subject areas

  • Ophthalmology

Cite this

What have we learnt about the management of diabetic macular edema in the antivascular endothelial growth factor and corticosteroid era? / Agarwal, Aniruddha; Sarwar, Salman; Sepah, Yasir J.; Nguyen, Quan D.

In: Current Opinion in Ophthalmology, Vol. 26, No. 3, 09.05.2015, p. 177-183.

Research output: Contribution to journalReview article

Agarwal, Aniruddha ; Sarwar, Salman ; Sepah, Yasir J. ; Nguyen, Quan D. / What have we learnt about the management of diabetic macular edema in the antivascular endothelial growth factor and corticosteroid era?. In: Current Opinion in Ophthalmology. 2015 ; Vol. 26, No. 3. pp. 177-183.
@article{29e91b4ad507420385f49debfad6023b,
title = "What have we learnt about the management of diabetic macular edema in the antivascular endothelial growth factor and corticosteroid era?",
abstract = "Purpose of review To summarize the outcomes of the use of antivascular endothelial growth factor (anti-VEGF) agents and corticosteroids on the treatment paradigm for diabetic macular edema (DME). Recent findings Favorable efficacy data along with acceptable long-term safety results of anti-VEGF agents have made them the standard first-line therapy in the management of DME. Level I evidence from large, multicenter clinical trials has established the beneficial role of anti-VEGF agents and intravitreal steroids. In addition, the role of anti-VEGF agents in the treatment of diabetic retinopathy has also been recently recognized. However, concerns such as suboptimal response, VEGF resistance, and long-term effects on retinal layers and vasculature have also been highlighted recently. Summary The use of anti-VEGF agents and corticosteroids has revolutionized the management of DME. Despite the advantages including ease of administration, low incidence of adverse events, and concomitant improvement in retinopathy status, limitations of this therapeutic approach have been recognized. The current review will focus on the lessons learnt in the management of DME in the anti-VEGF and steroid era.",
keywords = "antivascular endothelial growth factor, corticosteroids, diabetic macular edema, intravitreal injection, laser photocoagulation, neovascularization, vascular endothelial growth factor",
author = "Aniruddha Agarwal and Salman Sarwar and Sepah, {Yasir J.} and Nguyen, {Quan D.}",
year = "2015",
month = "5",
day = "9",
doi = "10.1097/ICU.0000000000000152",
language = "English (US)",
volume = "26",
pages = "177--183",
journal = "Current Opinion in Ophthalmology",
issn = "1040-8738",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - What have we learnt about the management of diabetic macular edema in the antivascular endothelial growth factor and corticosteroid era?

AU - Agarwal, Aniruddha

AU - Sarwar, Salman

AU - Sepah, Yasir J.

AU - Nguyen, Quan D.

PY - 2015/5/9

Y1 - 2015/5/9

N2 - Purpose of review To summarize the outcomes of the use of antivascular endothelial growth factor (anti-VEGF) agents and corticosteroids on the treatment paradigm for diabetic macular edema (DME). Recent findings Favorable efficacy data along with acceptable long-term safety results of anti-VEGF agents have made them the standard first-line therapy in the management of DME. Level I evidence from large, multicenter clinical trials has established the beneficial role of anti-VEGF agents and intravitreal steroids. In addition, the role of anti-VEGF agents in the treatment of diabetic retinopathy has also been recently recognized. However, concerns such as suboptimal response, VEGF resistance, and long-term effects on retinal layers and vasculature have also been highlighted recently. Summary The use of anti-VEGF agents and corticosteroids has revolutionized the management of DME. Despite the advantages including ease of administration, low incidence of adverse events, and concomitant improvement in retinopathy status, limitations of this therapeutic approach have been recognized. The current review will focus on the lessons learnt in the management of DME in the anti-VEGF and steroid era.

AB - Purpose of review To summarize the outcomes of the use of antivascular endothelial growth factor (anti-VEGF) agents and corticosteroids on the treatment paradigm for diabetic macular edema (DME). Recent findings Favorable efficacy data along with acceptable long-term safety results of anti-VEGF agents have made them the standard first-line therapy in the management of DME. Level I evidence from large, multicenter clinical trials has established the beneficial role of anti-VEGF agents and intravitreal steroids. In addition, the role of anti-VEGF agents in the treatment of diabetic retinopathy has also been recently recognized. However, concerns such as suboptimal response, VEGF resistance, and long-term effects on retinal layers and vasculature have also been highlighted recently. Summary The use of anti-VEGF agents and corticosteroids has revolutionized the management of DME. Despite the advantages including ease of administration, low incidence of adverse events, and concomitant improvement in retinopathy status, limitations of this therapeutic approach have been recognized. The current review will focus on the lessons learnt in the management of DME in the anti-VEGF and steroid era.

KW - antivascular endothelial growth factor

KW - corticosteroids

KW - diabetic macular edema

KW - intravitreal injection

KW - laser photocoagulation

KW - neovascularization

KW - vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84926628113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926628113&partnerID=8YFLogxK

U2 - 10.1097/ICU.0000000000000152

DO - 10.1097/ICU.0000000000000152

M3 - Review article

C2 - 25784111

AN - SCOPUS:84926628113

VL - 26

SP - 177

EP - 183

JO - Current Opinion in Ophthalmology

JF - Current Opinion in Ophthalmology

SN - 1040-8738

IS - 3

ER -